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Background: Psychiatric adverse drug reactions (ADRs) are distressing for patients and have important public
health implications. We identified the drugs with the most frequent spontaneous reports of depression, and fatal
and non-fatal suicidal behaviour to the UK’s Yellow Card Scheme from 1998 to 2011.
Methods: We obtained Yellow Card data from the Medicines and Healthcare products Regulatory Agency for the
drugs with the most frequent spontaneous reports of depression and suicidal behaviour from 1964 onwards.
Prescribing data were obtained from the NHS Information Centre and the Department of Health. We examined the
frequency of reports for drugs and estimated rates of reporting of psychiatric ADRs using prescribing data as proxy
denominators from 1998 to 2011, as prescribing data were not available prior to 1998.
Results: There were 110 different drugs with≥ 20 reports of depression, 58 with ≥10 reports of non-fatal suicidal
behaviour and 33 with ≥5 reports of fatal suicidal behaviour in the time period. The top five drugs with the most frequent
reports of depression were the smoking cessation medicines varenicline and bupropion, followed by paroxetine (a selective
serotonin reuptake inhibitor), isotretinoin (used in acne treatment) and rimonabant (a weight loss drug). Selective serotonin
reuptake inhibitors, varenicline and the antipsychotic medicine clozapine were included in the top five medicines with the
most frequent reports of fatal and non-fatal suicidal behaviour. Medicines with the highest reliably measured reporting
rates of psychiatric ADRs per million prescriptions dispensed in the community included rimonabant, isotretinoin,
mefloquine (an antimalarial), varenicline and bupropion. Robust denominators for community prescribing were not
available for two drugs with five or more suicide reports, efavirenz (an antiretroviral medicine) and clozapine.
Conclusions: Depression and suicide-related ADRs are reported for many nervous system and non-nervous system
drugs. As spontaneous reports cannot be used to determine causality between the drug and the ADR, psychiatric ADRs
which can cause significant public alarm should be specifically assessed and reported in all randomised controlled trials.
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Adverse effectsBackground
Adverse drug reactions (ADRs) cost the UK’s NHS up to
£2 billion each year [1]. In recent years there has been
growing concern that certain prescribed medicines may
be associated with psychiatric adverse drug reactions
such as depression, non-fatal self-harm and suicide [2,3].* Correspondence: kyla.thomas@bristol.ac.uk
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unless otherwise stated.The occurrence of medication induced suicide is par-
ticularly distressing to the general public. In the UK,
television programmes such as the British Broadcasting
Company (BBC) programme “Secrets of Seroxat” which
was first aired in October 2002 and “Dying for clear
skin” shown in November 2012, have attracted record
viewing figures and public response [4,5]. These docu-
mentaries focussed on the possible risk of suicide with
the antidepressant paroxetine and isotretinoin (used to
treat severe acne) and showed that drug- induced psy-
chiatric ADRs have the potential to cause significantl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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if unfounded safety concerns result in the reduced use of
effective medicines. When a drug is first licensed for use
in the general population, there is limited information
about its possible adverse effects, as pre-marketing drug
trials are underpowered to detect rare psychiatric ADRs
such as suicide [6]. Therefore post marketing surveillance
using spontaneous reporting systems is crucial, particu-
larly for rare outcomes. However, only a small number of
studies have systematically described the medicines which
are associated with spontaneous reports of psychiatric
ADRs [7-10]; to the best of our knowledge, this has never
been done before in the UK.
The aim of this paper is to identify the drugs with
the most frequent reporting of suspected psychiatric
ADRs to the UK’s Yellow Card Scheme from 1998 to
2011. We focus on depression and fatal and non-fatal
suicidal behaviour. Although drug induced suicide is
the psychiatric ADR that is most likely to cause sig-
nificant public concern, we also include reports of de-
pressive illness and non-fatal suicidal behaviour which




The Yellow Card Scheme is used by the Medicines and
Healthcare products Regulatory Agency (MHRA) to moni-
tor the safety of currently licensed medicines and vaccines
in the UK and is part of routine pharmacovigilance. Cur-
rently, health professionals (doctors, dentists, nurses, and
pharmacists), coroners, patients, parents and carers are
encouraged to report ‘suspected’ adverse drug reactions
to the scheme using paper Yellow Cards or electronic
reports (https://YellowCard.mhra.gov.uk accessed 27th
February 2014).
We received preliminary data from the MHRA on all
spontaneous reports to the Yellow Card Scheme from
its creation in 1964 until the 25th January 2012 using the
following Higher Level Terms (HLTs) from the Medical
Dictionary for Regulatory Affairs (MedDRA): (a) Depressive
disorders; and (b) Suicidal and self injurious behaviour.
Details of the Preferred Terms (PTs) which are included
in the HLTs are shown in Additional file 1. Due to the
large number of drugs involved (Yellow Card reports of
depressive disorders were received for 872 medicines, re-
ports of non-fatal suicidal behaviour were received for 425
medicines and reports of fatal suicidal behaviour were re-
ceived for 196 medicines) we requested detailed individual
reports for drugs using the following pragmatically selected
thresholds:
1. Twenty or more reports for depressive disorders
with a non-fatal outcome.2. Ten or more reports for suicidal and self injurious
behaviour with a non-fatal outcome
3. Five or more reports for suicidal and self injurious
behaviour with a fatal outcome
For reports of suicidal and self injurious behaviour as-
sociated with a fatal outcome (i.e. completed suicide),
the MHRA also provided us with information regarding
whether the medicine had also been taken in overdose;
this is important as in some cases suicide may have been
the result of the deliberate ingestion of excessive quan-
tities of medicines (e.g. self poisoning with pain killers
such as paracetamol and co-proxamol) and not actually
an adverse effect of the drug. Additionally, new European
Union (EU) legislation has amended the definition of the
term adverse reaction to include unintended effects from
unauthorised as well as authorised use of medication [12].
Age- and sex- specific data were provided in an aggre-
gated format and were not available for individual reports.
Data were anonymised, so the suspected ADR could not
be linked to either the patient or the reporter. We ob-
tained permission for use of Yellow Card data from the In-
dependent Scientific Advisory Committee for MHRA
database research. Ethics approval was not required for
this study as Category 1b data are releaseable under the
Freedom of Information Act (FOIA) 2000.Prescribing data
Prescription cost analysis (PCA) data provide details of
the number of items and the net ingredient cost of all
prescriptions which have been dispensed in the commu-
nity in England. Yearly prescription cost analysis data for
England from 1998 to 2011 were obtained from the NHS
Information Centre (http://www.hscic.gov.uk/prescribing
accessed 13th September 2012) and used as crude proxy
denominators for the yearly use of individual drugs. Indi-
vidual drug data on the number of prescriptions dispensed
were not available prior to 1998.
For drugs that were not commonly prescribed in the
community (we defined this as <100 000 prescriptions
in the 14 year study period) we also obtained data from
2008–2011 on hospital usage of medicines by acute trusts
from the Commercial Medicines Unit of the Department
of Health (cmu.dh.gov.uk). These data provided an estima-
tion of yearly usage for those medicines that are more
likely to be prescribed in hospitals than by general practi-
tioners (GPs) in the community. Hospital usage data were
not available prior to 2008.Classification of medicines
We used the 2014 Anatomical Therapeutic Chemical
(ATC) classification system to categorise the medicines
[13]. Medicines are classified based on their main
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code for each route of administration.
We stratified the medicines into nervous system medi-
cations and non-nervous system medications according
to their ATC classification to assess whether our psychi-
atric outcomes of interest were more likely to be re-
ported for nervous system drugs than drugs which affect
other systems. Although bupropion is only licensed for
use as a smoking cessation medicine in the UK, its ATC
code was changed in 2009 from ATC level 5 N07BA02
(under ATC level 4 N07BA- Drugs used in nicotine
dependence) to N06AX12 (under ATC level 4 NO6AX-
Other antidepressants) to represent its main indication
worldwide (personal communication WHO Collaborat-
ing Centre for Drug Statistics Methodology).
Statistical analyses
Stata version 12.0 (StataCorp, USA) and Excel 2007
(Microsoft, USA) were used for the analyses. We pro-
duced frequency tables for the drugs (all, nervous sys-
tem and non nervous system drugs) with the most
frequent reports of depression and non-fatal and fatal
suicidal behaviour from 1998 to 2011. For drugs with
reports of fatal suicidal behaviour we also examined the
percentage of these reports that included ingestion of
the specific medicine in an overdose (i.e. self-poisoning
with the medicine).
We calculated overall rates of reporting of suspected
ADRs per million prescriptions from 1998 to 2011 using
the number of reports for each drug as the numerator
and the number of prescriptions for each drug from the
PCA data as the denominator [14]. Scatter plots of the
reporting rates of depressive disorders versus non-fatal
suicidal behaviour and versus suicide were created and
Spearman’s correlation coefficients were calculated to
examine possible correlations between the rates of report-
ing of depression with non-fatal and fatal suicidal behav-
iour. We used Spearman’s correlation coefficient as it is a
non parametric method which does not assume that the
data are normally distributed; this is particularly relevant
in small samples.
Results
Psychiatric ADR reporting 1964–2012
Over the entire time period (1964 to 25th January 2012)
there were 6800 Yellow Card reports (35.8% male) of
depressive disorders, 3624 reports (42.5% male) of non-
fatal suicidal behaviour and 664 reports (69.6% male) of
suicide; these reports were 1.65% of all reports made to
the database. The ratio of reports of non-fatal to fatal
suicidal behaviour was 5.5: 1. Eighteen to 35 year olds
accounted for 24.6% of reports of depressive disorders,
28.9% of reports of non-fatal suicidal behaviour and
29.7% of suicide reports. People aged 36 to 65 yearsaccounted for 47.7% of reports of depressive disorders,
43.8% of reports of non-fatal suicidal behaviour and 48.2%
of suicide reports. Ten percent of reports of depressive
disorders, 4.2% of non-fatal suicidal behaviour reports and
7.1% of suicide reports were from people aged ≥ 66 years.
Reports and prescribing 1998–2011
Using our thresholds, there were 110 different drugs
with 20 or more Yellow Card reports of depressive disor-
ders, 58 with 10 or more reports of non-fatal suicidal be-
haviour and 33 with five or more reports of suicide from
January 1st 1998 to December 31st 2011.
For all drugs, the top five medicines for reports of de-
pressive disorders were the smoking cessation medi-
cines, varenicline (1st) and bupropion (2nd), paroxetine, a
selective serotonin reuptake inhibitor (SSRI) antidepres-
sant (3rd), isotretinoin, used in acne treatment (4th) and
rimonabant, a weight loss drug (5th). The top five medi-
cines for reports of non-fatal suicidal behaviour were par-
oxetine (1st), varenicline (2nd), the SSRI antidepressants
citalopram (3rd) and fluoxetine (4th) and clozapine, an
antipsychotic (5th). With the exception of varenicline and
clozapine all of the drugs with the highest reporting of
non-fatal suicidal behaviour are SSRIs. The drug with the
most frequent reports of suicide was clozapine, an anti-
psychotic agent (1st), followed by three SSRIs, citalopram
(2nd), fluoxetine (3rd) and paroxetine (4th) and a serotonin
noradrenaline reuptake inhibitor (SNRI), venlafaxine (5th).
Although bupropion and isotretinoin were in the top five
for reports of depressive disorders, for reports of non-
fatal suicidal behaviour, bupropion was ranked 7th and iso-
tretinoin was ranked 11th. For suicide, bupropion was
ranked 22nd and isotretinoin was ranked 7th. Although
varenicline was ranked 1st for reports of depressive disor-
ders and second for reports of non-fatal suicidal behav-
iour, for suicide it was ranked 6th. Unlike the other
smoking cessation drugs, there were only 17 Yellow Card
reports of depressive disorders, five reports of non-fatal
suicidal behaviour and no reports of suicide for nicotine
replacement therapy.
Figure 1 shows the distribution of the major drug clas-
ses of the top 20 medicines with the greatest number of
Yellow Card reports of depressive disorders, non-fatal
suicidal behaviour and suicide. Reports of psychiatric ad-
verse reactions were most frequently observed for anti-
depressants (20% of drugs in the top 20 for reports of
depressive disorders, 40% for reports of non-fatal suicidal
behaviour and 45% for suicide reports). Antipsychotic
agents were also commonly implicated (25% of suicide re-
ports and 15% of reports of non-fatal suicidal behaviour) as
well as anticonvulsants (10% of reports of depressive disor-
ders and 15% of reports of non-fatal suicidal behaviour).
Other drug classes such as smoking cessation drugs,
weight loss medicines and antimalarials also had frequent
Figure 1 Distribution of major classes of the Top 20 medicines
with the highest numbers of Yellow Card reports for
depressive disorders and fatal and non-fatal suicidal behaviour.
Table 1 Percentage of Yellow Card reports for suicides
where the implicated drug was taken in an episode of
fatal self-poisoning from 1998 to 2011
Drug Number of suicide
reports
Percentage of overdose






























*Bupropion is licensed for use as an antidepressant in other countries but not
the UK.
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10% of reports of depressive disorders and non-fatal
suicidal behaviour, 5% of suicide reports; weight loss
medicines- 10% of reports of depressive disorders; and
antimalarials- 5% of reports of depressive disorders and
suicide).
With the exception of varenicline, bupropion and par-
oxetine, most of the top 10 drugs with reports of depres-
sive disorders are treatments for non nervous system
indications such as isotretinoin (an anti-acne preparation),
rimonabant (an anti-obesity preparation), simvastatin (a
lipid modifying agent), mefloquine (an antimalarial), levo-
norgestrel (a hormone), atorvastatin (a lipid modifying
agent) and rofecoxib (an anti-inflammatory and antirheu-
matic product). However for reports of non-fatal and fatal
suicidal behaviour, most of the top 10 drugs were nervous
system drugs such as antidepressants, antipsychotics and
the smoking cessation medicines.
The drugs (nervous system drugs versus non nervous
system drugs) with reports of more than one psychiatric
ADR stratified by ATC level 1 classification are listed in
Additional file 2. Table 1 shows the percentage of Yellow
Card reports of suicide which involved intentional over-
dose (i.e. deliberate ingestion of the medicines). Drugs
that were commonly implicated in fatal overdose were
aspirin, where 100% of suicide reports involved deliber-
ate ingestion of the drug, followed by 66.7% for trama-
dol, a narcotic analgesic, 61.5% for zopiclone, a hypnotic
medicine and 60% for paracetamol (an analgesic).
Rates of ADRs 1998–2011
In order to account for how often the drug is prescribed
we describe reporting rates using community prescribing
data next (Table 2). Although the SSRI antidepressants
(paroxetine, fluoxetine and citalopram) had the mostfrequent reports of depressive disorders and fatal and
non-fatal suicidal behaviour, reporting rates were low as
these drugs are widely prescribed. Additionally, simva-
statin had a much lower reporting rate of depressive dis-
orders than mefloquine (0.4 per million prescriptions
versus 457 per million) although there was a similar
number of reports (110 versus 105 respectively).
For medicines in the top 20 that were more commonly
prescribed in secondary care such as efavirenz and clo-
zapine, rates were re-calculated using hospital prescrib-
ing data for the most recent years. The rate of reporting
for efavirenz was 27.4 per million hospital prescriptions
Table 2 Rates of Yellow Card adverse reports per million prescriptions dispensed for the top 20 drugs with the highest
number of adverse reports for depressive disorders, non-fatal suicidal behaviour and suicide




Non-nervous system drugs Rimonabant 190 773 667-891
Isotretinoin 199 553 479-636
Mefloquine 105 457 373-553
Etonogestrel 51 82 61-108
Sibutramine 55 25 19-33
Levonorgestrel 86 14 12-18
Desogestrel 64 9 7-12
Rofecoxib 73 9 7-12
Montelukast 45 5 3-6
Atorvastatin 74 0.6 0.5-0.8
Simvastatin 110 0.4 0.3-0.5
Nervous system drugs Clozapine 50 630 468-831
Bupropion* 483 330 301-361
Varenicline 975 248 233-264
Topiramate 61 18 14-23
Levetiracetam 66 15 12-19
Paroxetine 263 8 7-9
Venlafaxine 57 2 2-3
Fluoxetine 56 0.9 0.7-1.2
Citalopram 56 0.7 0.5-0.9
Non-fatal suicidal behaviour
Non-nervous system drugs Rimonabant 74 30 236-378
Isotretinoin 71 197 154-249
Nervous system drugs Clozapine 132 1664 1393-1973
Atomoxetine 126 230 192-274
Varenicline 675 172 159-185
Bupropion* 117 80 66-96
Duloxetine 97 32 26-39
Paroxetine 709 21 19-22
Levetiracetam 69 16 12-20
Topiramate 37 11 8-15
Pregabalin 47 6 5-8
Escitalopram 61 6 4-7
Venlafaxine 113 4 3-5
Risperidone 49 3 3-5
Mirtazapine 67 3 3-4
Olanzapine 48 3 2-4
Citalopram 219 3 2-3
Fluoxetine 161 3 2-3
Sertraline 51 2 1-3
Paracetamol 69 0.4 0.3-0.5
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Table 2 Rates of Yellow Card adverse reports per million prescriptions dispensed for the top 20 drugs with the highest
number of adverse reports for depressive disorders, non-fatal suicidal behaviour and suicide (Continued)
Suicide
Non-nervous system drugs Efavirenz 7 2312 930-4757
Isotretinoin 32 89 61-126
Mefloquine 8 35 15-69
Nervous system drugs Clozapine 78 984 778-1227
Varenicline 41 10 8-14
Duloxetine 28 9 6-13
Aripiprazole 15 9 5-14
Risperidone 24 2 1-3
Paroxetine 50 2 1-2
Venlafaxine 42 1 1-2
Olanzapine 24 1 0.9-2
Escitalopram 15 1 0.8-2
Quetiapine 13 1 0.6-2
Fluoxetine 58 0.9 0.7-1
Citalopram 70 0.8 0.7-1
Mirtazapine 17 0.8 0.5-1
Sertraline 21 0.8 0.5-1
Zopiclone 13 0.2 0.1-0.4
Diazepam 11 0.2 0.1-0.3
Amitryptiline 6 0.1 0.03-0.2
*Bupropion is licensed for use as an antidepressant in other countries but not the UK.
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prescriptions) which would move efavirenz from 1st to
3rd place for non nervous system drugs associated with
suicide (see Table 2). Clozapine had a reporting rate of
19.7 per million hospital prescriptions for depressive
disorders (630 per million community prescriptions),
62.3 per million hospital prescriptions for non-fatal
suicidal behaviour (1664 per million community pre-
scriptions) and 36.3 per million hospital prescriptions
for suicide (984 per million community prescriptions).
Therefore clozapine remained at the top of the rankings
for nervous system drugs with the highest reporting rate
of suicide.
Figure 2 shows scatter plots of the reporting rates of
non-fatal suicidal behaviour versus depressive disorders
and suicide versus depressive disorders for nervous sys-
tem versus non nervous system drugs (see Additional
file 2). Clozapine and efavirenz were excluded as these
drugs are not commonly prescribed in the community.
For nervous system drugs there was positive correlation
between reporting rates of non-fatal suicidal behaviour
and depressive disorders (n = 14, Spearman’s rho 0.88,
p < 0.001) as well as for suicide and depressive disorders
(n = 9 Spearman’s rho 0.88, p < 0.01). For non- nervoussystem drugs there was slightly weaker positive correl-
ation between the rates for non-fatal suicidal behaviour
and depression (n = 11, Spearman’s rho 0.78, p < 0.01).
Reports of depressive disorders and suicide were observed




Reports of drug induced depression and fatal and non-
fatal suicidal behaviour constitute a very small minority
of total ADR reports. We found that the drugs with the
highest frequency of Yellow Card reports of psychiatric
ADRs included nervous system medicines such as the
SSRI antidepressants, smoking cessation medicines vareni-
cline and bupropion and the antipsychotic drug clozapine
as well as non-nervous system drugs such as isotretinoin
(used in acne treatment) and mefloquine (an antimalarial).
Reports of depression were most frequently observed for
non nervous system drugs; most reports of suicide and
non-fatal suicidal behaviour involved nervous system med-
icines. Analgesics (such as paracetamol) and hypnotics/
benzodiazepines were also likely to be implicated in reports
of suicide but most of these deaths were reported to have
Figure 2 Scatter plots of reporting rates of suicide versus rates of depressive disorders and rates of non-fatal suicidal behaviour
versus rates of depressive disorders for nervous system medicines (excluding clozapine) and non nervous system medicines
(excluding efavirenz).
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of the drugs in overdose. Reporting rates for efavirenz and
clozapine were much lower when data on hospital usage
were used instead of community prescriptions as these
drugs are not likely to be prescribed in a primary care set-
ting. There was positive association between the reporting
rates of self-harm and depression and suicide and depres-
sion for nervous system and non-nervous system drugs.
Strengths and limitations
This is the first study to systematically describe the
reporting of depression and fatal and non-fatal suicidal
behaviour to the UK’s Yellow Card Scheme although it
excludes other psychiatric adverse drug reactions, such
as anxiety, psychosis and insomnia. Strengths include
the 14 years of reporting and the inclusion of drug
utilisation data (prescribing data) to calculate reporting
rates. We examined the reports from all medicines that
met pre-defined thresholds for inclusion and stratified
the medicines by their ATC level 1 classification. The
occurrence of Yellow Card reports of suspected ADRs
with a specific drug does not indicate that the drug defin-
itely caused the ADR as there are many factors that have
to be taken into consideration when assessing causal rela-
tionships, such as the timing of when the drug was taken
in relation to the outcome, the biological plausibility, the
possible contribution of concomitant medication and the
underlying disease [15].
Additionally, the reporting of ADRs using Yellow
Cards is affected by the extent of use of a particular drug,
whether the drug is newly licensed (i.e. length of time ofdrug on the market) [16], stimulated reporting caused by
safety warnings about a drug (notoriety bias) [17], adverse
media publicity about a drug and the seriousness of the
ADR [18]. In our study there were 5.5 times as many non-
fatal suicidal behaviour as suicide reports, whereas the
ratio of non-fatal self-harm to suicide in the general popu-
lation is 30:1[19]. This is likely to have occurred because
more serious (or fatal) adverse reactions are reported
more often. Under-reporting is a serious issue; only 6% of
ADRs in hospital and general practice are reported in
the UK [20,21]. Also, drugs such as oral contraceptives
and beta blockers which have long been recognised as
associated with depression, were likely to have low
numbers of reports in our study period, as Yellow Card
reporting decreases the longer the drug has been avail-
able on the market [18]. Over the counter medicines,
such as nicotine replacement therapy, may also be sub-
ject to under-reporting.
Due to the large numbers of drugs with reports of our
psychiatric ADRs of interest, we used specific thresholds
to request detailed individual reports. Although this
approach is likely to have identified those medicines
which would have potentially caused the most harm, it
may have missed drugs which are rarely prescribed, but
which have a high ratio of reports to prescriptions and
drugs which have only recently been marketed with low
consumption.
The number of Yellow Card reports received cannot
be used to determine the actual incidence rate of an
ADR as both the total number of reactions occurring
and the number of patients who actually used the drug
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data as a proxy). We used PCA data for the number of
prescriptions dispensed in the community to estimate a
rate of ADR reports per million prescriptions of the
drug; this is a very crude estimation and did not include
standardisation by age or sex or take account of the aver-
age duration of prescribing or the indication for which the
drug was prescribed. Age and sex standardisation are im-
portant as most non-fatal suicidal behaviour occurs in
women and at younger ages when general drug prescrib-
ing is rarer [22]. The importance of using proxy denomi-
nators to estimate reporting rates was shown by the stark
contrast in the reporting rates of depression for meflo-
quine and simvastatin, although similar numbers of abso-
lute reports were obtained for both medicines.
Certain drugs, such as efavirenz and clozapine are more
often prescribed in hospitals, which resulted in under-
estimation of the denominator and over-estimation of
reporting rates in our analyses using community prescrip-
tions. Reporting rates were much lower when hospital
prescribing data were used although these data were only
available for a more limited time period. Additionally,
clozapine is subject to extensive monitoring for adverse
effects such as agranulocytosis; this would also increase
the reporting of other unrelated adverse effects. There-
fore the reporting pattern is likely to be very different
for clozapine compared with other medicines for which
reporting is truly spontaneous; limiting inference about
possible causal associations.
Disproportionality analysis is another method that is
often used to identify potential safety hazards or safety sig-
nals in spontaneous reporting data. Dal Pan et al. (2013)
defined disproportionality as “the finding that a given ad-
verse event/adverse drug reaction is reported for a par-
ticular drug more often than would be expected based
on the number of reports of that adverse event/adverse
drug reaction for all other drugs in the database” [23].
This method has several advantages over the use of proxy
denominator data to calculate reporting rates because it is
not affected by changes in the reporting of ADRs and does
not require the use of external data sources [23]. Statistical
methods for determining disproportionality include the
use of the proportional reporting ratio (PRR), which can
be interpreted in a similar manner to a risk ratio (i.e. a
higher ratio indicates a stronger signal) [24]. However, the
aim of this study was to provide a descriptive overview of
the drugs associated with frequent Yellow card reports of
depressive disorders and fatal and non-fatal self-harm as
opposed to identifying new safety signals.
Evidence from other studies of worldwide spontaneous
reporting systems
Few studies have examined the spontaneous reporting of
psychiatric ADRs [7-10]. Robertson and Allison (2009)used the Food and Drug Administration Adverse Event
Reporting System (FDA AERS) to examine whether drugs
associated with reports of suicidal ideation were also asso-
ciated with reports of suicide attempts and found that
many different classes of drugs were associated with both
outcomes [10]. One recent study examined the reporting
of psychiatric ADRs in the Swedish paediatric population
using the Swedish Drug Information System (SWEDIS)
database. In keeping with our analysis, this study found
that isotretinoin, antiepileptics, SSRIs and montelukast
(used in the treatment of asthma) were frequently associ-
ated with serious psychiatric ADRs [7]. Other frequently
implicated drugs included vaccines, centrally working sym-
pathomimetics and melatonin. An earlier study looked at
reports to Canada’s adverse drug reaction database from
1965 until the early 1990s. Adrenergic drugs (clonidine
and methyldopa), beta blockers (propranolol), corticoste-
roids, benzodiazepines and oral contraceptives were associ-
ated with more than 10 reports of depression although
none of these drugs featured prominently in our analysis,
probably because we focussed on later years and reports of
ADRs decrease the longer a particular drug has been on
the market [8]. Vilhelmsson et al. (2011) looked at reports
of psychiatric ADRs with antidepressant medication that
were made to a consumer association in Sweden [9]. De-
pression was reported as an ADR for citalopram, escitalo-
pram and paroxetine. Suicidal behaviour was reported as a
psychiatric ADR for all included antidepressants, mainly
SSRIs and serotonin noradrenaline reuptake inhibitors
(SNRIs). These findings are also consistent with our ana-
lysis. Last, Aagaard and Hansen (2013) examined ADRs
reported by consumers in Europe for nervous system med-
ications including antiepileptics, antidepressants and smok-
ing cessation medicines [25]. Most of the ADRs were
reported for psychiatric disorders which also accounted for
the majority of ADRs categorised as serious [25].
Other methods used to investigate psychiatric ADRs
There are three main explanations for the higher fre-
quency of reports of depression and suicidal behaviour
observed with certain drugs. First, the drug may have a
causal role in triggering the adverse drug reaction. Sec-
ond, the drug may have no causal role but is used in a
condition which increases the risk of developing the ad-
verse outcome, for example an association between anti-
depressants and suicide may be explained by the fact
that depression itself is a risk factor for suicide [11].
Third, the drug may or may not have a causal role but
there are reasons why patients, healthcare professionals
and other individuals are more likely to send in a spon-
taneous report for the drug. For example, in the UK
there was an increase in spontaneous reports of ADRs
for paroxetine following adverse media publicity from
the BBC Panorama programmes which suggested an
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[26]. In addition, the association between isotretinoin
and inflammatory bowel disease observed in the FDA
AERS has been explained by an excess of lawyer-
initiated reports related to pending isotretinoin lawsuits
[27]. Although spontaneous reporting systems are im-
portant for identifying previously unknown ADRs, RCTs
and meta-analyses of RCTs are the preferred study de-
signs for the evaluation of drug therapies, as if properly
conducted, they provide the strongest evidence of caus-
ality between exposure to a particular drug and the out-
come of interest [28]. The strongest evidence of adverse
psychiatric ADRs comes from meta-analyses of placebo
controlled randomised controlled trials (RCTs). These
show increased risk of self-harm and suicidal thinking
in children prescribed SSRIs such as paroxetine com-
pared with placebo (3.7% vs 2.5%, RR 1.51:95% CI 0.62
to 3.69) [29]. Such evidence has resulted in regulatory
action to restrict the use of SSRIs in young people
in many countries. The authorisation for rimonabant
was suspended by the European Medicines Agency in
October 2008 because its adverse psychiatric effects,
particularly depression, were felt to outweigh its benefits
as a mildly effective weight loss drug [2]. These findings
were also obtained from meta-analyses of randomised
controlled trials and are in keeping with our findings of a
high reporting rate of depression and non-fatal self-harm
with rimonabant [30].
More recently, the MHRA in the UK and their equiva-
lent in the US, the Food and Drug Administration (FDA),
have issued warnings in relation to certain drugs such as
varenicline, based on spontaneous reports of suspected
ADRs in individual cases from the Yellow Card Scheme in
the UK and its equivalent in the USA [31]. Prescription
event monitoring studies have found conflicting results; a
study carried out in New Zealand found that varenicline
use was associated with more reports of suicide and sui-
cidal ideation whereas a more recent study in England did
not find any evidence for an increase in reports of depres-
sion and other neuropsychiatric adverse events with
varenicline [32,33]. However, observational cohort studies
have not found any definitive evidence that varenicline
and bupropion are associated with increased suicidal be-
haviour [17,34].
In June 2009 the FDA requested the addition of infor-
mation regarding neuropsychiatric adverse effects to the
precautions section of montelukast prescribing informa-
tion [35]. A review of Merck drug company trials failed
to identify any completed suicides associated with its use
[36], a finding supported by analysis of a large primary
care database in the UK [37]. A meta-analysis of suicidal
risk during treatment with clozapine also found a lower
overall risk of suicidal behaviour associated with cloza-
pine compared with other treatments for psychosis [38].Although efavirenz has been associated with spontan-
eous reports of psychiatric ADRs, there was no clear
evidence from a systematic review that patients taking
efavirenz were at increased risk of suicide [39]. A recent
review found little evidence for an increased risk of sui-
cide and suicidal behaviour with antidepressants, anti-
epileptics, varenicline, montelukast and antipsychotics
[40]. It is reassuring that, with the exception of SSRIs in
young people, other study designs have not confirmed
elevated risks of neuropsychiatric adverse effects for
medicines with high numbers of spontaneous reports in
our study.
Conclusions
Spontaneous Yellow Card reports of depression and
suicide-related ADRs were obtained for many different
classes of drugs including nervous system drugs such as
antidepressants, antipsychotics and smoking cessation
medicines, in addition to non- nervous system drugs such
as weight loss medicines and drugs used in the treatment
of acne. Although we could not examine emerging safety
concerns for recently marketed drugs, it is reassuring that
no new drugs were identified. As spontaneous reports of
ADRs do not indicate causal associations between drugs
and adverse reactions, we suggest that psychiatric adverse
events which can cause significant public alarm such as
suicide, suicidal behaviour and depression should be spe-
cifically monitored and reported in all randomised con-
trolled trials.
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